Tolerance of mefloquine chemoprophylaxis in Dutch military personnel

American Journal of Tropical Medicine and Hygiene

Volumn 55, Issue 2, 1996, Pages 230-234

  Jaspers, C A J J ^a   Hopperus Buma, A P C C ^b   Van Thiel, P P A M ^c   Van Hulst, R A ^b   Kager, P A ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Royal Netherlands Navy   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; MEFLOQUINE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALARIA; MALE; MILITARY SERVICE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; QT INTERVAL; VERTIGO;

ANIMALIA;

EID: 0029782191     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.55.230     Document Type: Article

References (15)

1. Boudreau E, Schuster B, Sanchez J, Novakowski W Johnson R, Redrnond D, Hanson R, Dausel L, 1993. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44: 257-265.
2. Karbwang J, White NJ, 1990. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264-279.
3. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE, 1990. A comparative study of gastrointestinal infections in United States soldiers recieving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 43: 608-613.
4. Reisinger EC, Horstmann RD, Dietrich M, 1989. Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg 83: 474-477.
5. Weinke T, Trautmann M, Held T, 1991. Neuropsychiatrie side effects after the use of mefloquine. Am J Trop Med Hyg 45: 86-91.
6. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, Phillips-Howard P, Nevill C, Sturchler D, 1993. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 341: 1299-1303.
7. Lobel HO, Bernard KW, Williams SL, Hightower AW, Patchen LC, Campbell CC, 1991. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. JAMA 265: 361-364.
8. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC, 1993. Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848-851.
9. Ekue JMK, Ulrich AM, Rwaowogo-Atenyi J, Sheth UK, 1983. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ 61: 713-718.
10. Laothavorn P, Karbwang J, Na Bangchang K, Bunnag D, Harisunata T, 1992. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients. South-east Asian J Trop Med Public Health 23: 51-54.
11. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ, 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056.
12. Jackman WM, Clark M, Friday KJ, Aliot EM, Anderson J, Lazzara R, 1984. Ventricular tachyarrhythmias in the long QT syndromes. Med Clin North Am 68: 1079-1102.
13. Palmer KJ, Holliday SM, Brogden RN, 1993. Mefloquine. A review of its antimalarial activity, pharmacokinetic, properties and therapeutic efficacy. Drugs 45: 430-475.
14. Bergvist Y, Hellgren U, Churchill F, 1988. High-performance liquid chromatographic assay for the simultaneous monitoring of mefloquine and its acids and acid-metabolite in biological samples using protein precipitations and ion per extraction. J Chromatogr 432: 253-263.
15. Gardner MJ, Altman DG, 1989. Statistics with Confidence. London: British Medical Journal.